NASDAQ:XERS - Xeris Pharmaceuticals Stock Price, Forecast & News

Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."

Xeris Pharmaceuticals Inc (NASDAQ:XERS) posted its quarterly earnings results on Thursday, November, 7th. The company reported ($1.22) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.23) by $0.01. The business had revenue of $0.32 million for the quarter, compared to the consensus estimate of $0.20 million. Xeris Pharmaceuticals had a negative return on equity of 150.08% and a negative net margin of 6,697.33%. View Xeris Pharmaceuticals' Earnings History.

Xeris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Xeris Pharmaceuticals.

3 Wall Street analysts have issued 12 month price targets for Xeris Pharmaceuticals' shares. Their forecasts range from $12.00 to $22.00. On average, they expect Xeris Pharmaceuticals' share price to reach $17.33 in the next twelve months. This suggests a possible upside of 300.3% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals.

News stories about XERS stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Xeris Pharmaceuticals earned a media sentiment score of -1.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Xeris Pharmaceuticals.

Some companies that are related to Xeris Pharmaceuticals include Organogenesis (ORGO), ProQR Therapeutics (PRQR), Recro Pharma (REPH), INDIVIOR PLC/S (INVVY), AnaptysBio (ANAB), Avedro (AVDR), Cue Biopharma (CUE), Progenics Pharmaceuticals (PGNX), Mirum Pharmaceuticals (MIRM), Verrica Pharmaceuticals (VRCA), Avid Bioservices (CDMO), Mallinckrodt (MNK), DURECT (DRRX), Mersana Therapeutics (MRSN) and Rigel Pharmaceuticals (RIGL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include Amicus Therapeutics (FOLD), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Agile Therapeutics (AGRX), Amarin (AMRN), Kala Pharmaceuticals (KALA), Omeros (OMER), Strongbridge Biopharma (SBBP), TG Therapeutics (TGTX) and InVitae (NVTA).

(XERS) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager.

Xeris Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Citigroup Inc. (8.15%), ArrowMark Colorado Holdings LLC (7.14%), State Street Corp (1.85%), Blackstone Group Inc (1.67%), IHT Wealth Management LLC (0.34%) and Bank of New York Mellon Corp (0.31%). Company insiders that own Xeris Pharmaceuticals stock include Beth Hecht, James E Flynn, John Patrick Shannon Jr, Palmetto Partners, Ltd, Paul R Edick, Redmile Group, Llc and Steven Prestrelski. View Institutional Ownership Trends for Xeris Pharmaceuticals.

XERS stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Goldman Sachs Group Inc. and Bank of America Corp DE. View Insider Buying and Selling for Xeris Pharmaceuticals.

XERS stock was acquired by a variety of institutional investors in the last quarter, including Citigroup Inc., Blackstone Group Inc, ArrowMark Colorado Holdings LLC, California Public Employees Retirement System, State Street Corp, IHT Wealth Management LLC, Marshall Wace LLP and Marshall Wace North America L.P.. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include Beth Hecht, James E Flynn, John Patrick Shannon Jr, Palmetto Partners, Ltd, Paul R Edick and Redmile Group, Llc. View Insider Buying and Selling for Xeris Pharmaceuticals.

Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XERS stock can currently be purchased for approximately $4.33.

Xeris Pharmaceuticals has a market capitalization of $116.91 million and generates $2.46 million in revenue each year. The company earns $-60,080,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Xeris Pharmaceuticals employs 90 workers across the globe.View Additional Information About Xeris Pharmaceuticals.

The official website for Xeris Pharmaceuticals is http://www.xerispharma.com/.

Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected]